

# David S Perlin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3002554/publications.pdf>

Version: 2024-02-01

144  
papers

8,048  
citations

53794

45  
h-index

56724

83  
g-index

153  
all docs

153  
docs citations

153  
times ranked

7873  
citing authors

#	ARTICLE	IF	CITATIONS
1	The global problem of antifungal resistance: prevalence, mechanisms, and management. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e383-e392.	9.1	670
2	Resistance to echinocandin-class antifungal drugs. <i>Drug Resistance Updates</i> , 2007, 10, 121-130.	14.4	440
3	Mechanisms of Antifungal Drug Resistance. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a019752.	6.2	419
4	A multicentre study of antifungal susceptibility patterns among 350 <i>Candida auris</i> isolates (2009-2017) in India: role of the <i>ERG11</i> and <i>FKS1</i> genes in azole and echinocandin resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 891-899.	3.0	380
5	Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. <i>Nature Microbiology</i> , 2018, 3, 415-422.	13.3	338
6	COVID-19 Associated Pulmonary Aspergillosis (CAPA) – From Immunology to Treatment. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 91.	3.5	292
7	Echinocandin Resistance in <i>Candida</i> . <i>Clinical Infectious Diseases</i> , 2015, 61, S612-S617.	5.8	248
8	Prevalent mutator genotype identified in fungal pathogen <i>Candida glabrata</i> promotes multi-drug resistance. <i>Nature Communications</i> , 2016, 7, 11128.	12.8	227
9	Current perspectives on echinocandin class drugs. <i>Future Microbiology</i> , 2011, 6, 441-457.	2.0	215
10	Mechanisms of echinocandin antifungal drug resistance. <i>Annals of the New York Academy of Sciences</i> , 2015, 1354, 1-11.	3.8	214
11	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 211.	3.5	170
12	Understanding Echinocandin Resistance in the Emerging Pathogen <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	165
13	Discovery of MRSA active antibiotics using primary sequence from the human microbiome. <i>Nature Chemical Biology</i> , 2016, 12, 1004-1006.	8.0	149
14	Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen <i>Candida auris</i> . <i>Journal of Clinical Microbiology</i> , 2017, 55, 2445-2452.	3.9	140
15	Update on Antifungal Drug Resistance. <i>Current Clinical Microbiology Reports</i> , 2015, 2, 84-95.	3.4	130
16	Limited <i>ERG11</i> Mutations Identified in Isolates of <i>Candida auris</i> Directly Contribute to Reduced Azole Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	125
17	Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium. <i>Antibiotics</i> , 2020, 9, 877.	3.7	125
18	Fungal Resistance to Echinocandins and the MDR Phenomenon in <i>Candida glabrata</i> . <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 105.	3.5	98

#	ARTICLE	IF	CITATIONS
19	Fungal Plasma Membrane Proton Pumps as Promising New Antifungal Targets. <i>Critical Reviews in Microbiology</i> , 1994, 20, 209-223.	6.1	86
20	The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 138.	3.5	84
21	Antifungal drug resistance: do molecular methods provide a way forward?. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 568-573.	3.1	82
22	Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management. <i>Drugs</i> , 2014, 74, 1573-1585.	10.9	82
23	Identification of Drug Resistant <i>Candida auris</i> . <i>Frontiers in Microbiology</i> , 2019, 10, 1918.	3.5	80
24	Genetic Drivers of Multidrug Resistance in <i>Candida glabrata</i> . <i>Frontiers in Microbiology</i> , 2016, 7, 1995.	3.5	77
25	Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	73
26	Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 70, 723-730.	5.8	73
27	Cochleates: New Lipid-Based Drug Delivery System. <i>Journal of Liposome Research</i> , 2000, 10, 523-538.	3.3	72
28	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment 1 IMPS is an investor in and consultant for Urogen. SAP is consultant and advisor for Vaccinex. The remaining authors have nothing to disclose.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 14-20.	1.6	67
29	CD101: a novel long-acting echinocandin. <i>Cellular Microbiology</i> , 2016, 18, 1308-1316.	2.1	66
30	Tolerance to Caspofungin in <i>Candida albicans</i> Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of <i>FKS</i> Genes and Cell Wall Remodeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	64
31	Direct Detection of Emergent Fungal Pathogen <i>Candida auris</i> in Clinical Skin Swabs by SYBR Green-Based Quantitative PCR Assay. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	63
32	Breakthrough Candidemia Due to Multidrug-Resistant <i>Candida glabrata</i> during Prophylaxis with a Low Dose of Micafungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2438-2440.	3.2	61
33	Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in <i>Cryptococcus neoformans</i> . <i>MBio</i> , 2016, 7, .	4.1	60
34	Fluconazole and Echinocandin Resistance of <i>Candida glabrata</i> Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance. <i>Frontiers in Microbiology</i> , 2016, 7, 2038.	3.5	59
35	<i>De Novo</i> Acquisition of Resistance to SCY-078 in <i>Candida glabrata</i> Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	57
36	First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant <i>Candida parapsilosis</i> Isolates Harboring Y132F and/or Y132F+K143R in Turkey. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	57

#	ARTICLE	IF	CITATIONS
37	Emergence of Echinocandin Resistance Due to a Point Mutation in the <i>FKS1</i> Gene of <i>Aspergillus fumigatus</i> in a Patient with Chronic Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	55
38	Cross-Resistance of Clinical Isolates of <i>Candida albicans</i> and <i>Candida glabrata</i> to Over-the-Counter Azoles Used in the Treatment of Vaginitis. <i>Microbial Drug Resistance</i> , 2000, 6, 155-161.	2.0	53
39	Rapid Detection of <i>FKS</i> -Associated Echinocandin Resistance in <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6573-6577.	3.2	53
40	Coping with Stress and the Emergence of Multidrug Resistance in Fungi. <i>PLoS Pathogens</i> , 2015, 11, e1004668.	4.7	52
41	Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation. <i>Biosensors and Bioelectronics</i> , 2020, 169, 112572.	10.1	52
42	Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs. <i>Journal of Fungi (Basel)</i> , 2020, 6, 107.	3.5	52
43	Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Infectious Diseases</i> , 2019, 220, 666-676.	4.0	51
44	Changes in In Vitro Susceptibility Patterns of <i>Aspergillus</i> to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015. <i>Clinical Infectious Diseases</i> , 2017, 65, 216-225.	5.8	50
45	Rapid Detection of ERG11 -Associated Azole Resistance and FKS -Associated Echinocandin Resistance in <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	49
46	Stress-Induced Changes in the Lipid Microenvironment of $\beta$ -(1,3)-D-Glucan Synthase Cause Clinically Important Echinocandin Resistance in <i>Aspergillus fumigatus</i> . <i>MBio</i> , 2019, 10, .	4.1	48
47	Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen <i>Candida glabrata</i> . <i>Scientific Reports</i> , 2017, 7, 9099.	3.3	47
48	Absence of Azole or Echinocandin Resistance in <i>Candida glabrata</i> Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	47
49	Caspofungin Uptake Is Mediated by a High-Affinity Transporter in <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3845-3849.	3.2	46
50	Biosynthesis of cell wall mannan in the conidium and the mycelium of <i>Aspergillus fumigatus</i> . <i>Cellular Microbiology</i> , 2016, 18, 1881-1891.	2.1	46
51	Set of Classical PCRs for Detection of Mutations in <i>Candida glabrata FKS</i> Genes Linked with Echinocandin Resistance. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2609-2614.	3.9	44
52	Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification. <i>Journal of Infectious Diseases</i> , 2017, 216, S458-S465.	4.0	40
53	Environmental Clonal Spread of Azole-Resistant <i>Candida parapsilosis</i> with Erg11-Y132F Mutation Causing a Large Candidemia Outbreak in a Brazilian Cancer Referral Center. <i>Journal of Fungi (Basel)</i> , 2020, 6, 107.	3.5	40
54	The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of <i>Candida glabrata</i> Colonization and Systemic Dissemination. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	38

#	ARTICLE	IF	CITATIONS
55	Multilocus Sequence Typing (MLST) Genotypes of <i>Candida glabrata</i> Bloodstream Isolates in Korea: Association With Antifungal Resistance, Mutations in Mismatch Repair Gene (Msh2), and Clinical Outcomes. <i>Frontiers in Microbiology</i> , 2018, 9, 1523.	3.5	38
56	Membrane-Disrupting Nanofibrous Peptide Hydrogels. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 4657-4670.	5.2	38
57	Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Survival and Infection Burden in Vivo. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8337-8352.	6.4	35
58	Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing <i>Klebsiella pneumoniae</i> Strains with Various <i>ompK36</i> Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3521-3525.	3.2	34
59	Low level of antifungal resistance of <i>Candida glabrata</i> blood isolates in Turkey: Fluconazole minimum inhibitory concentration and <i>FKS</i> mutations can predict therapeutic failure. <i>Mycoses</i> , 2020, 63, 911-920.	4.0	34
60	Clonal Candidemia Outbreak by <i>Candida parapsilosis</i> Carrying Y132F in Turkey: Evolution of a Persisting Challenge. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 676177.	3.9	34
61	<i>FKS2</i> and <i>FKS3</i> Genes of Opportunistic Human Pathogen <i>Candida albicans</i> Influence Echinocandin Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	33
62	Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS. <i>MSphere</i> , 2020, 5, .	2.9	33
63	Significantly Improved Pharmacokinetics Enhances <i>In Vivo</i> Efficacy of APX001 against Echinocandin- and Multidrug-Resistant <i>Candida</i> Isolates in a Mouse Model of Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	32
64	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn6859.	12.4	31
65	Spontaneous Mutational Frequency and <i>FKS</i> Mutation Rates Vary by Echinocandin Agent against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
66	Novel <i>FKS1</i> and <i>FKS2</i> modifications in a high-level echinocandin resistant clinical isolate of <i>Candida glabrata</i> . <i>Emerging Microbes and Infections</i> , 2019, 8, 1619-1625.	6.5	29
67	Genetically related micafungin-resistant <i>Candida parapsilosis</i> blood isolates harbouring novel mutation R658G in hotspot 1 of <i>Fks1p</i> : a new challenge?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 418-422.	3.0	29
68	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>JCI Insight</i> , 2021, 6, .	5.0	29
69	Adipose Tissue Regulates Pulmonary Pathology during TB Infection. <i>MBio</i> , 2019, 10, .	4.1	27
70	Molecular diagnostic platforms for detecting <i>Aspergillus</i> . <i>Medical Mycology</i> , 2009, 47, S223-S232.	0.7	26
71	Extracellular Vesicle Capture by Antibody of Choice and Enzymatic Release (EV-CATCHER): A customizable purification assay designed for small RNA biomarker identification and evaluation of circulating sEVs. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12110.	12.2	26
72	Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 192.	3.5	25

#	ARTICLE	IF	CITATIONS
73	Cross-Species Infectivity of H3N8 Influenza Virus in an Experimental Infection in Swine. <i>Journal of Virology</i> , 2015, 89, 11190-11202.	3.4	24
74	VT-1598 inhibits the in vitro growth of mucosal <i>Candida</i> strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2089-2094.	3.0	23
75	Direct Molecular Diagnosis of Aspergillosis and CYP51A Profiling from Respiratory Samples of French Patients. <i>Frontiers in Microbiology</i> , 2016, 7, 1164.	3.5	21
76	Recent Increase in the Prevalence of Fluconazole-Non-susceptible <i>Candida tropicalis</i> Blood Isolates in Turkey: Clinical Implication of Azole-Non-susceptible and Fluconazole Tolerant Phenotypes and Genotyping. <i>Frontiers in Microbiology</i> , 2020, 11, 587278.	3.5	21
77	Breakthrough candidaemia caused by phenotypically susceptible <i>Candida</i> spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 248-255.	2.5	20
78	Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	20
79	A Preclinical Candidate Targeting <i>Mycobacterium tuberculosis</i> KasA. <i>Cell Chemical Biology</i> , 2020, 27, 560-570.e10.	5.2	20
80	Echinocandin-Resistant <i>Candida</i> : Molecular Methods and Phenotypes. <i>Current Fungal Infection Reports</i> , 2011, 5, 113-119.	2.6	19
81	An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant <i>Acinetobacter baumannii</i> -Infected Wounds. <i>MSphere</i> , 2018, 3, .	2.9	19
82	Molecular Diagnostics in the Times of Surveillance for <i>Candida auris</i> . <i>Journal of Fungi (Basel)</i> , 2020, 6, 19. <a href="https://doi.org/10.3390/jof6010019">https://doi.org/10.3390/jof6010019</a>	3.5	19
83	Host Biomarkers of Invasive Pulmonary Aspergillosis To Monitor Therapeutic Response. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3373-3378.	3.2	18
84	A Novel, Drug Resistance-Independent, Fluorescence-Based Approach To Measure Mutation Rates in Microbial Pathogens. <i>MBio</i> , 2019, 10, .	4.1	18
85	A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women. <i>Frontiers in Microbiology</i> , 2021, 12, 655069.	3.5	18
86	Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Medicine</i> , 2021, 8, 649675.	2.6	18
87	An Aptamer-Based Biosensor for the Azole Class of Antifungal Drugs. <i>MSphere</i> , 2017, 2, .	2.9	18
88	<i>Clostridium difficile</i> infection in Brazil: A neglected problem?. <i>American Journal of Infection Control</i> , 2014, 42, 459-460.	2.3	16
89	Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in <i>Candida albicans</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 2037-2041.	3.9	16
90	Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16

#	ARTICLE	IF	CITATIONS
91	Preliminary Structural Elucidation of $\beta$ -(1,3)-glucan Synthase from <i>Candida glabrata</i> Using Cryo-Electron Tomography. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 120.	3.5	16
92	Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	16
93	Detection of <i>Candida auris</i> Antifungal Drug Resistance Markers Directly from Clinical Skin Swabs. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
94	A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens. <i>ACS Infectious Diseases</i> , 2020, 6, 2431-2440.	3.8	15
95	Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018). <i>Medical Mycology</i> , 2021, 59, 422-430.	0.7	15
96	A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations. <i>Emerging Microbes and Infections</i> , 2021, 10, 994-997.	6.5	15
97	Critical Assessment of Cell Wall Integrity Factors Contributing to in vivo Echinocandin Tolerance and Resistance in <i>Candida glabrata</i> . <i>Frontiers in Microbiology</i> , 2021, 12, 702779.	3.5	15
98	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
99	Efficacy of LAMB against Emerging Azole- and Multidrug-Resistant <i>Candida parapsilosis</i> Isolates in the <i>Galleria mellonella</i> Model. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 377.	3.5	14
100	A Noncanonical DNA Damage Checkpoint Response in a Major Fungal Pathogen. <i>MBio</i> , 2020, 11, .	4.1	14
101	Target Enzyme Mutations Confer Differential Echinocandin Susceptibilities in <i>Candida kefyr</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5421-5427.	3.2	13
102	Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream <i>Candida</i> Infections from a Tertiary Hospital in Qatar. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	13
103	Multidrug-resistant <i>Trichosporon</i> species: underestimated fungal pathogens posing imminent threats in clinical settings. <i>Critical Reviews in Microbiology</i> , 2021, 47, 679-698.	6.1	13
104	A novel, tomographic imaging probe for rapid diagnosis of fungal keratitis. <i>Medical Mycology</i> , 2018, 56, 796-802.	0.7	12
105	Comparative study of <i>Candida</i> spp. isolates: Identification and echinocandin susceptibility in isolates obtained from blood cultures in 15 hospitals in Medellín, Colombia. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 13, 254-260.	2.2	12
106	Dose escalation studies with caspofungin against <i>Candida glabrata</i> . <i>Journal of Medical Microbiology</i> , 2015, 64, 998-1007.	1.8	12
107	Differential Regulation of Echinocandin Targets Fks1 and Fks2 in <i>Candida glabrata</i> by the Post-Transcriptional Regulator Ssd1. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 143.	3.5	11
108	Diagnosis, clinical characteristics, and outcomes of COVID-19 patients from a large healthcare system in northern New Jersey. <i>Scientific Reports</i> , 2021, 11, 4389.	3.3	11

#	ARTICLE	IF	CITATIONS
109	Methylprednisolone Enhances the Growth of <i>Exserohilum rostratum</i> In Vitro, Attenuates Spontaneous Apoptosis, and Increases Mortality Rates in Immunocompetent <i>Drosophila</i> Flies. <i>Journal of Infectious Diseases</i> , 2014, 210, 1471-1475.	4.0	10
110	Fungal DNA Detected in Blood Samples of Patients Who Received Contaminated Methylprednisolone Injections Reveals Increased Complexity of Causative Agents. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2212-2215.	3.9	10
111	Cell Wall-Modifying Antifungal Drugs. <i>Current Topics in Microbiology and Immunology</i> , 2019, 425, 255-275.	1.1	10
112	A multicentre study to optimize echinocandin susceptibility testing of <i>Aspergillus</i> species with the EUCAST methodology and a broth microdilution colorimetric method. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1799-1806.	3.0	10
113	Blood <i>Aspergillus</i> RNA is a promising alternative biomarker for invasive aspergillosis. <i>Medical Mycology</i> , 2016, 54, 801-807.	0.7	9
114	Beyond tissue concentrations: antifungal penetration at the site of infection. <i>Medical Mycology</i> , 2019, 57, S161-S167.	0.7	9
115	Echinocandin Resistance in <i>Aspergillus fumigatus</i> Has Broad Implications for Membrane Lipid Perturbations That Influence Drug-Target Interactions. <i>Microbiology Insights</i> , 2019, 12, 117863611989703.	2.0	9
116	Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant <i>Candida tropicalis</i> : An Emerging Threat to Immunocompromised Patients with Hematological Malignancies. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 20.	3.5	9
117	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2247-2254.	3.0	8
118	Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. <i>Medical Mycology</i> , 2019, 57, 38-44.	0.7	8
119	Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-Resistant <i>Staphylococcus aureus</i> . <i>ACS Infectious Diseases</i> , 2021, 7, 2508-2521.	3.8	8
120	Amphotericin B cochleates: a vehicle for oral delivery. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 198-201.	2.3	8
121	<i>Cryptococcus</i> flips its lid - membrane phospholipid asymmetry modulates antifungal drug resistance and virulence. <i>Microbial Cell</i> , 2016, 3, 358-360.	3.2	7
122	Albumin Enhances Caspofungin Activity against <i>Aspergillus</i> Species by Facilitating Drug Delivery to Germinating Hyphae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1226-1233.	3.2	7
123	Methylprednisolone impairs conidial phagocytosis but does not attenuate hyphal damage by neutrophils against <i>Exserohilum rostratum</i> . <i>Medical Mycology</i> , 2015, 53, 189-193.	0.7	6
124	A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs. <i>MSphere</i> , 2018, 3, .	2.9	6
125	Performance Evaluation of Culture-Independent SYBR Green <i>Candida auris</i> Quantitative PCR Diagnostics on Anterior Nares Surveillance Swabs. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	6
126	Comparative Pharmacodynamics of Echinocandins against <i>Aspergillus fumigatus</i> Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6



#	ARTICLE	IF	CITATIONS
127	Antifungal Drug Susceptibility and Genetic Characterization of Fungi Recovered from COVID-19 Patients. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 552.	3.5	6
128	Role of $\beta$ (1-3)-glucan in <i>Aspergillus fumigatus</i> and other human fungal pathogens. , 2007, , 269-288.		5
129	DNA damage response of major fungal pathogen <i>Candida glabrata</i> offers clues to explain its genetic diversity. <i>Current Genetics</i> , 2021, 67, 439-445.	1.7	5
130	Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>PLoS Pathogens</i> , 2021, 17, e1010025.	4.7	5
131	Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against <i>Candida albicans</i> and <i>Candida dubliniensis</i> . <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1805-1814.	2.7	4
132	Clinical and microbiological features of candiduria in critically ill adult patients in Shiraz, Iran (2016–2018): deviations from international guidelines and fluconazole therapeutic failure. <i>Medical Mycology</i> , 2021, 59, 600-607.	0.7	4
133	Multiplex Detection of Mutations. <i>Methods in Molecular Biology</i> , 2008, 429, 23-31.	0.9	3
134	Expression Dynamics of Innate Immunity in Influenza Virus-Infected Swine. <i>Frontiers in Veterinary Science</i> , 2017, 4, 48.	2.2	2
135	Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I (a Phase 3 Randomized, Double-blind) Trial for Acute Pyelonephritis. <i>Open Forum Infectious Diseases</i> , 2017, 4, S536-S536.	0.9	1
136	2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, S711-S711.	0.9	1
137	Antifungal Mechanisms of Action and Resistance. , 0, , 457-466.		1
138	Reply to “Detection of Multiple Fungal Species in Blood Samples by Real-Time PCR: an Interpretative Challenge”, <i>Journal of Clinical Microbiology</i> , 2014, 52, 3517-3517.	3.9	0
139	Reply to “Not Over Yet: Fungal Infections following Methyl Prednisolone Injections Smoulder On”, <i>Journal of Clinical Microbiology</i> , 2014, 52, 3508-3508.	3.9	0
140	Welcome Message from the Editor-in-Chief. <i>Journal of Fungi</i> (Basel, Switzerland), 2015, 1, 1-3.	3.5	0
141	Echinocandin-resistant <i>Candida tropicalis</i> Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2017, 4, S284-S285.	0.9	0
142	Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model. <i>Open Forum Infectious Diseases</i> , 2017, 4, S479-S479.	0.9	0
143	The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a <i>Candida glabrata</i> Colonization Mouse Model. <i>Open Forum Infectious Diseases</i> , 2017, 4, S129-S129.	0.9	0
144	Antifungal Consideration for Transplant Recipients. , 2019, , 927-940.		0